PUBLISHER: The Business Research Company | PRODUCT CODE: 1951596
PUBLISHER: The Business Research Company | PRODUCT CODE: 1951596
Cellular immunotherapy is a type of immunotherapy in which a patient is given T cells, a type of immune cell, to help the body fight diseases such as cancer. It is an advanced form of treatment that harnesses the body's immune system to target cancer.
The main therapies in cellular immunotherapy include tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, and natural killer (NK) cell therapy. Tumor-infiltrating lymphocyte (TIL) therapy is a form of adoptive cellular therapy that involves isolating lymphocytes that have infiltrated tumors, expanding and culturing them in vitro, and then reintroducing them into patients for treatment. The primary indications include B-cell malignancies, prostate cancer, renal cell carcinoma, liver cancer, non-Hodgkin lymphoma, among others, and it is applied in the treatment of prostate cancer, breast cancer, skin cancer, ovarian cancer, brain tumors, lung cancer, and additional types of cancer.
Tariffs have raised the cost of imported cell therapy equipment, single use systems, and specialized reagents used in advanced therapy manufacturing. These impacts are most evident in Europe and Asia, where cell therapy developers rely on cross border sourcing for critical inputs. Rising tariff related expenses have increased production costs and influenced investment planning for cell based therapies. This has affected scale up timelines and capacity expansion decisions. However, tariffs are also encouraging regional manufacturing capabilities, local supplier ecosystems, and greater self sufficiency in advanced therapy production over the long term.
The cellular immunotherapy market research report is one of a series of new reports from The Business Research Company that provides cellular immunotherapy market statistics, including cellular immunotherapy industry global market size, regional shares, competitors with a cellular immunotherapy market share, detailed cellular immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the cellular immunotherapy industry. This cellular immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cellular immunotherapy market size has grown rapidly in recent years. It will grow from $6.56 billion in 2025 to $7.48 billion in 2026 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to success of early car-t therapies, unmet oncology needs, research funding growth, regulatory approvals, academic-industry collaboration.
The cellular immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $12.5 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to expansion into solid tumors, innovation in nk cell therapy, scalable manufacturing technologies, supportive regulatory frameworks, increased oncology investment. Major trends in the forecast period include rapid growth of car-t cell therapies, expansion of allogeneic cell therapies, increasing use in hematologic malignancies, advancements in t cell engineering, rising clinical trial activity.
The increasing prevalence of cancer is expected to drive the expansion of the cellular immunotherapy market in the coming years. Cancer comprises a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. The rise in cancer cases is largely attributed to an aging population, lifestyle choices, and advancements in screening and diagnosis. Environmental exposures and genetic predispositions also significantly contribute to the increasing incidence. Cellular immunotherapy enhances the immune system's response against cancer by specifically targeting tumor cells, thereby improving survival rates. When used alongside other treatments, this approach may contribute to a reduction in cancer incidence and recurrence. For example, in March 2024, MAC Clinical Research, a UK-based cancer research organization, reported that the estimated number of people living with cancer in the United Kingdom is expected to rise from around 3 million currently to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the rising prevalence of cancer is propelling the growth of the cellular immunotherapy market.
Major companies operating in the cellular immunotherapy market are concentrating on developing technological innovations such as immunotherapy to improve treatment effectiveness and broaden its applications. Their focus areas include personalized medicine, combination therapies, and scalable manufacturing to enhance patient outcomes. Immunotherapy is a treatment that leverages the body's immune system to combat diseases, particularly cancer. It may involve enhancing immune responses or delivering targeted therapies to boost immune activity against specific cells. For example, in December 2023, Max Healthcare Institute Limited, an India-based healthcare service provider, highlighted CAR-T cell therapy, a groundbreaking cancer treatment that uses genetically engineered T cells to precisely target and eliminate cancer cells, offering a personalized strategy. This therapy provides long-lasting remission rates, especially for treatment-resistant blood cancers, while minimizing harm to healthy tissues.
In January 2023, AstraZeneca, a UK-based pharmaceutical company, acquired Neogene Therapeutics for an undisclosed amount. Through this acquisition, AstraZeneca intends to strengthen its oncology portfolio and accelerate the development of innovative T-cell receptor therapies for solid tumors via Neogene Therapeutics. Neogene Therapeutics, Inc., a US-based biotechnology firm, specializes in personalized cellular immunotherapy, engineering T-cells to specifically target cancer cells.
Major companies operating in the cellular immunotherapy market are Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation
North America was the largest region in the cellular immunotherapy market in 2025. The regions covered in the cellular immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cellular immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cellular immunotherapy market includes revenues earned by entities by inventing, developing, administering, and understanding engineered immune effector cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cellular Immunotherapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses cellular immunotherapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for cellular immunotherapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cellular immunotherapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.